| 胡明乐,宋 斌,刘 颖,陈靖赜,郭晓红.布地奈德福莫特罗粉吸入剂联合孟鲁斯特对支气管哮喘急性发作期患者肺功能及血清细胞因子水平的影响[J].现代生物医学进展英文版,2020,(16):3113-3116. |
| 布地奈德福莫特罗粉吸入剂联合孟鲁斯特对支气管哮喘急性发作期患者肺功能及血清细胞因子水平的影响 |
| Effect of Symbicort Turbuhaler Combined with Montelukast on Pulmonary Function and Serum Cytokine Levels in Patients with Acute Stage of Bronchial Asthma |
| Received:January 30, 2020 Revised:February 24, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.16.024 |
| 中文关键词: 布地奈德福莫特罗粉吸入剂 孟鲁斯特 支气管哮喘 急性发作期 肺功能 细胞因子 |
| 英文关键词: Symbicort Turbuhaler Montelukast Bronchial asthma Acute attack stage Pulmonary function Cytokines |
| 基金项目:湖北省自然科学基金项目（2017CFB703） |
| Author Name | Affiliation | E-mail | | HU Ming-le | Department of Pharmacy, Wuhan Jinyintan Hospital, Wuhan, Hubei, 430023, China | minglehu2012@126.com | | SONG Bin | Department of Respiratory Medicine, Wuhan Jinyintan Hospital, Wuhan, Hubei, 430023, China | | | LIU Ying | Drug Clinical Trial Institution, Wuhan Jinyintan Hospital, Wuhan, Hubei, 430023, China | | | CHEN Jing-ze | Department of Pharmacy, Wuhan Jinyintan Hospital, Wuhan, Hubei, 430023, China | | | GUO Xiao-hong | Department of Pharmacy, Wuhan Jinyintan Hospital, Wuhan, Hubei, 430023, China | |
|
| Hits: 761 |
| Download times: 483 |
| 中文摘要: |
| 摘要 目的：研究布地奈德福莫特罗粉吸入剂（ST）联合孟鲁斯特对支气管哮喘急性发作期（ASBA）患者肺功能及血清细胞因子水平的影响。方法：选择2015年2月到2017年8月在我院治疗的86例ASBA患者作为研究对象，根据随机数字表法将患者分成观察组（n=43）以及对照组（n=43），对照组予以ST治疗，观察组则在此基础上联合孟鲁司特治疗，两组均治疗3个月，对比两组患者治疗前及治疗3个月后的肺功能、细胞因子水平、咳嗽评分、St?George's 呼吸疾病问卷（SGRQ）以及用药安全性。结果：治疗后两组患者的第1秒的用力呼气容积（FEV1）、用力肺活量（FVC）及FEV1/FVC均较治疗前升高，且观察组高于对照组（P<0.05）。治疗后两组患者的白细胞介素-4（IL-4）、白细胞介素-5（IL-5）、γ-干扰素（INF-γ）及肿瘤坏死因子-α（TNF-α）水平均较治疗前降低，且观察组低于对照组（P<0.05）。治疗后两组患者的咳嗽评分较治疗前升高，且观察组高于对照组（P<0.05），而治疗后两组患者的SGRQ评分均较治疗前降低，且观察组低于对照组（P<0.05）。观察组不良反应的总发生率为20.93%，与对照组的16.28%相比无统计学差异（P>0.05）。结论：ASBA给予ST联合孟鲁司特治疗能够有效改善患者的症状，缓解机体炎症反映的同时还可有效改善患者肺功能和生活质量，其用药安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To study effect of symbicort turbuhaler(ST) combined with montelukast on pulmonary function and serum cytokine levels in patients with acute stage of bronchial asthma(ASBA). Methods: 86 patients with ASBA who were treated in our hospital from February 2015 to August 2017 were selected as research subjects. The patients were divided into the observation group (n=43) and the control group (n=43) according to the random number table method. The control group was treated with ST, and the observation group was treated with montelukast on the basis of the control group, two groups were treated for 3 months. The lung function, cytokine levels, cough score, St. George's respiratory disease questionnaire (SGRQ) before treatment and 3 months after treatment and drug safety were compared between the two groups. Results: After treatment, the levels of forced expiratory volume (FEV1), forced vital capacity (FVC) and FEV1/FVC in the two groups were increased significantly compared with those before treatment, and the observation group was higher than that of the control group (P<0.05). After treatment, the levels of interleukin-4 (IL-4), interleukin-5 (IL-5), interferon-γ (INF-γ) and tumor necrosis factor-α (TNF-α) in the two groups were all lower than those before treatment, and the observation group was lower than that in the control group (P<0.05). After treatment, the scores of cough in two groups were significantly higher than before treatment, and the observation group was significantly higher than the control group(P<0.05). After treatment, the scores of SGRQ in two groups were significantly lower than before treatment, and the observation group was significantly lower than the control group(P<0.05). The total incidence of adverse reactions in the observation group was 20.93%, and there was no statistical difference compared with 16.28% of the control group (P>0.05). Conclusion: ST combined with montelukast can effectively improve the symptoms of the ASBA patients, alleviate the inflammatory reaction of the body and improve the pulmonary function and quality of life of the patients at the same time. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
